The Global Rheumatoid Arthritis Therapeutics Market is estimated to grow at a CAGR of 4.8% during the forecast period 2018-2025. As per the analysis, the global market was valued $23,822.5 Million in the year 2017 and is estimated to reach $33,988.2 million by the end of the year 2025.
GET FREE SAMPLE COPY @ https://www.reportocean.com/industry-verticals/sample-request?report_id=BWC95
Rheumatoid arthritis has an estimated prevalence of 1-2% worldwide. The disease prevalence increases with age that approach ~5% in women of above age 55 years. In the U.S., the average annual incidence accounted to about 70 per 100,000 per year. Both prevalence and incidence of rheumatoid arthritis are two to three times higher in women than in men. The disease can affect at any age, but is highly prevalent in the age range of late 30s to 60s. With the advancements and innovative solutions available in the market, prevalence of rheumatoid arthritis has been reduced till some extent.
The Global Rheumatoid Arthritis Therapeutics Market is driven by various growth factors such as increase in number of geriatric populations worldwide—high prevalence of rheumatoid arthritis among aged population. Improvement in diagnostic procedures, spread of various awareness programs and increasing number of skilled healthcare professionals are further boosting the market growth for the forecast period.
Segmentation Overview of the Global Rheumatoid Arthritis Therapeutics Market
The global rheumatoid arthritis therapeutics market is segmented on the basis of product and distribution channel. These major market segments are further categorized into various sub-segments to study the market in detail.
The Product Segment of the Global Rheumatoid Arthritis Therapeutics Market is Sub-Segmented into:
The Distribution Channel Segment of the Global Rheumatoid Arthritis Therapeutics Market is Sub-Segmented into:
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
Geographical Overview of the Global Rheumatoid Arthritis Therapeutics Market
On the basis of geographical segmentation, the global rheumatoid arthritis therapeuticsmarket was studied across North America (U.S., Canada); Europe (Germany, UK, France); Asia Pacific (China, India, Japan); Latin America (Brazil, Mexico); Middle East & Africa and Rest of the World. As per the analysis, the North American market accounted to $9,929.6 million in the year 2017 and estimated to show a constant growth, owing to increasing prevalence of rheumatoid arthritis in the region and rising awareness about the disorder. Also, the government of the region are majorly investing to improve healthcare services and medical facilities. On the other side, the Asia Pacific rheumatoid arthritis therapeuticsmarket is estimated to grow at a significant growth rate with fastest CAGR. The regional growth is attributed to launch of new drugs in biologics that are majorly used in the treatment of rheumatoid arthritis. The growth of the APAC market is also influenced by increasing investment of the healthcare and medical infrastructure in emerging regions.
Key Players Insights
Pfizer, Gilead Sciences, Inc., Eli Lilly and Company, UCB S.A., Hoffmann-La Roche AG, Bristol-Myers Squibb Company, CELGENE CORPORATION, Johnson & Johnson Services, Inc. and Amgen Inc. are some major players included in the research study of the global rheumatoid arthritis therapeuticsmarket compiled by Report Ocean.
For more information about this report @ https://www.reportocean.com/industry-verticals/sample-request?report_id=BWC95
Company Name: Report Ocean
Contact Person: Nishi Sharma
Email: Send Email
Address:Classic Tower, Rajnagar Extension
State: UP, 201017